An Overview of Ovarian Cancer Treatment Options

An Introduction to Ovarian Cancer Treatment

Ovarian cancer treatment is a complex field that requires a highly specialized and multi-modal approach. Because its early symptoms are often vague, ovarian cancer is frequently diagnosed at an advanced stage when it has already spread within the abdominal cavity. The treatment strategy is determined by several critical factors: the specific type of ovarian cancer (the most common being epithelial), the stage of the disease, the tumor’s grade and molecular characteristics (such as the presence of a BRCA mutation), and the patient’s overall health and fitness for aggressive therapy.

For women diagnosed with early-stage disease confined to the ovary, the treatment goal is curative. For the majority who are diagnosed with advanced-stage disease, the primary goals are to remove as much of the cancer as possible, treat the remaining microscopic disease with medication, and then work to extend the period of remission for as long as possible.

The Role of the Gynecologic Oncology Team

Due to the unique and complex nature of this disease, it is widely recognized that women with suspected or diagnosed ovarian cancer should be treated by a gynecologic oncologist. This is a subspecialist who has completed training first in obstetrics and gynecology and then in a surgical and medical oncology fellowship focused exclusively on cancers of the female reproductive system.

The gynecologic oncologist typically leads a multidisciplinary team (MDT) that collaborates on the patient’s care. This team includes:

• Gynecologic Oncologist: Serves as both the surgeon and the medical oncologist who prescribes chemotherapy and other medications. Their specialized surgical skills are critical to patient outcomes.
• Pathologist: A physician who examines the tumor tissue to confirm the diagnosis, type, and grade of the cancer.
• Radiologist: A physician who interprets imaging studies like CT and PET scans to determine the extent of the disease before and after treatment.
• Genetic Counselor: A professional who assesses the patient’s personal and family history to provide guidance on genetic testing for hereditary cancer syndromes, such as those involving BRCA1 and BRCA2 genes.
• Palliative Care Specialist and Dietitian: Experts who help manage symptoms and nutritional needs throughout the treatment journey.

The Central Role of Surgery: Staging and Debulking

Surgery is the absolute cornerstone of ovarian cancer management and has two equally important goals: staging and debulking.

1. Staging: This is the process of surgically determining exactly where the cancer has spread. Accurate staging is essential for planning subsequent treatment. A comprehensive staging surgery involves a total hysterectomy (removal of the uterus), a bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes), an omentectomy (removal of the omentum, a fatty apron of tissue in the abdomen where the cancer often spreads), and sampling of lymph nodes and other tissues throughout the abdomen and pelvis.
2. Debulking (or Cytoreduction): For advanced-stage disease, the primary surgical goal is to remove as much visible tumor as possible from the abdominal cavity. The outcome of this surgery is one of the most important factors related to a patient’s prognosis. The goal is an “optimal debulking,” which ideally means no visible tumor is left behind at the completion of the surgery. When all visible tumor is removed, it is called a “complete cytoreduction.”

Systemic Therapy: The Role of Chemotherapy

Chemotherapy is a systemic treatment that uses powerful drugs to kill cancer cells throughout the body. For ovarian cancer, it is a critical component of treatment for nearly every stage.

• Adjuvant Chemotherapy: This is chemotherapy given after surgery to eliminate any microscopic cancer cells that could not be seen and removed. This is the standard approach for most women following their initial debulking surgery. The standard regimen for many years has been a combination of a platinum-based drug (like carboplatin) and a taxane drug (like paclitaxel), administered intravenously (IV) every three weeks for about six cycles.
• Neoadjuvant Chemotherapy: This is chemotherapy given before surgery. This approach is used for women who are diagnosed with very advanced Stage III or IV disease, or who may not be medically fit enough to undergo a lengthy and complex initial debulking operation. The goal is to shrink the tumors first, making a subsequent surgery (called interval debulking surgery) safer and more likely to be successful.
• Intraperitoneal (IP) Chemotherapy: For some select patients, chemotherapy can be delivered directly into the abdominal cavity through a surgically implanted port. This method allows a higher concentration of the drugs to come into direct contact with the cancer cells. It is a more intensive therapy with different side effects and is used less commonly today than in the past.

Targeted Therapies in Ovarian Cancer

In recent years, the development of targeted therapies has transformed the management of ovarian cancer. Unlike chemotherapy, which affects all rapidly dividing cells, targeted drugs are designed to attack specific vulnerabilities in cancer cells.

• PARP Inhibitors: This is the most important class of targeted drugs in ovarian cancer. Poly (ADP-ribose) polymerase (PARP) is an enzyme that helps repair damaged DNA in cells. Certain ovarian cancers, especially those with a BRCA gene mutation, have a faulty DNA repair system and are heavily dependent on PARP to survive. By blocking PARP, these drugs cause the cancer cells to die. PARP inhibitors have proven to be highly effective, particularly as a maintenance therapy.
• Anti-Angiogenesis Therapy: These drugs work by blocking a protein called VEGF, which tumors use to create new blood vessels to get the nutrients they need to grow. By inhibiting this process (angiogenesis), the drugs can help slow or shrink the cancer. They are typically given in combination with chemotherapy and can also be used as a maintenance therapy.

Maintenance Therapy: A Strategy to Delay Recurrence

Ovarian cancer has a high rate of recurrence, even after a good response to initial surgery and chemotherapy. Maintenance therapy is a strategy used after a patient has completed their initial chemotherapy course. The goal is not to cure the cancer but to prolong the period of remission and delay the time until the cancer may recur.

PARP inhibitors are the most widely used and effective agents for maintenance therapy. They are oral medications taken daily. They are offered to women with advanced-stage ovarian cancer who have had a complete or partial response to their initial platinum-based chemotherapy. While particularly effective for women with BRCA mutations, they have also shown benefit in a broader population of patients.

Frequently asked Questions

1. Why is it important to be treated by a gynecologic oncologist?
A gynecologic oncologist is a surgeon and physician with specialized training focused exclusively on cancers of the female reproductive system. Studies have consistently shown that women with ovarian cancer who have their initial surgery performed by a gynecologic oncologist have a more thorough staging and debulking procedure, which is one of the most critical factors for a better long-term outcome.

2. What does “debulking” surgery mean in ovarian cancer?
Debulking, or cytoreductive surgery, is the process of surgically removing as much visible tumor as possible from the abdomen and pelvis. The goal is “optimal debulking,” ideally leaving no visible cancer behind. This is crucial because the less tumor there is remaining after surgery, the more effective the subsequent chemotherapy is at killing the remaining microscopic cancer cells.

3. What are PARP inhibitors and how do they work?
PARP inhibitors are a class of oral targeted therapy drugs. They work by blocking PARP, an enzyme that cancer cells use to repair damage to their DNA. In ovarian cancers that already have a weakness in their DNA repair system (like those with a BRCA mutation), blocking PARP as well is lethal to the cancer cell. They are most often used as a maintenance therapy to delay cancer recurrence.

4. What is maintenance therapy and why is it used for ovarian cancer?
Maintenance therapy is a treatment strategy used after a patient has completed their initial chemotherapy. The goal is to extend the length of their remission and delay a potential recurrence. Because ovarian cancer has a high tendency to return, maintenance therapy with drugs like PARP inhibitors has become a standard part of care for many women with advanced disease.

5. What is the difference between neoadjuvant and adjuvant chemotherapy?
Adjuvant chemotherapy is given after the primary surgery to kill any remaining cancer cells. Neoadjuvant chemotherapy is given before surgery. This approach is used in advanced disease to shrink tumors, which can make a subsequent debulking surgery safer and more effective.

6. Why is genetic testing for mutations like BRCA important in ovarian cancer?
Genetic testing is important for two main reasons. First, it helps identify if the cancer is due to a hereditary syndrome, which has implications for the patient’s family members who may also be at risk. Second, it provides crucial information for treatment planning. Knowing a patient has a BRCA mutation makes them an ideal candidate for treatment with highly effective PARP inhibitors.

7. Is all ovarian cancer treated the same way?
No. While there are standard approaches, treatment is highly personalized. It depends on the specific type of ovarian cancer (e.g., epithelial, germ cell, stromal), the stage and grade of the cancer, the patient’s overall health, and, increasingly, the molecular and genetic makeup of the tumor.